Awakn Life Sciences Provides a Business and Corporate Update
Phase III Trial to Cost approximately CA$3.75 million with Awakn's contribution expected to be approximately CA$1.25 million, Marks First Psychedelic ...
Phase III Trial to Cost approximately CA$3.75 million with Awakn's contribution expected to be approximately CA$1.25 million, Marks First Psychedelic ...
The Company is scheduled to begin production and analytical testing of MDMA this October in its recently completed EU-GMP pharmaceutical ...
Advertise your site, company or product to millions of web3, NFT and cryptocurrency enthusiasts. Learn more
© 2022 Altszn.com. All Rights Reserved.